Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services Secretary ...

Shares of Novavax, Inc. (NVAX) plunged over 19.5% on Thursday after Health and Human Services Secretary Robert F. Kennedy Jr.

Shares of Novavax (NVAX) are under pressure on Thursday following Robert F. Kennedy Jr.’s comments on the company’s COVID shot approval delay.

BofA lowered the firm’s price target on Novavax (NVAX) to $10 from $12 and keeps a Neutral rating on the shares. Shares are sliding over 21% ...

The US Food and Drug Administration has delayed granting full approval of Novavax’s Covid-19 vaccine despite it being on ...

The FDA was supposed to make a final decision about approval of Novavax's COVID-19 vaccine this week, but that deadline has ...

Amid a period of great upheaval at the agency, the FDA has missed its deadline to decide on approval for Novavax’s COVID-19 ...

The agency is sitting on a decision to grant full approval for Novavax’s shot, days after top vaccine regulator pushed out.

The delayed decision comes amid a major organizational shakeup that included the departure of top vaccine official Peter ...

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings ...

The U.S. Food and Drug Administration has delayed granting full approval of Novavax's COVID-19 vaccine despite it being on track to be cleared until Tuesday afternoon, a person familiar with the ...